Compare · DXCM vs KMTS
DXCM vs KMTS
Side-by-side comparison of DexCom Inc. (DXCM) and Kestra Medical Technologies Ltd. (KMTS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DXCM and KMTS operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- DXCM is the larger of the two at $33.10B, about 19.4x KMTS ($1.71B).
- Over the past year, DXCM is up 29.2% and KMTS is up 10.4% - DXCM leads by 18.9 points.
- Both names hit the wire about 6 times in the past 4 weeks.
- DXCM has more recent analyst coverage (25 ratings vs 9 for KMTS).
- Company
- DexCom Inc.
- Kestra Medical Technologies Ltd.
- Price
- $86.05-1.93%
- $27.16-5.20%
- Market cap
- $33.10B
- $1.71B
- 1M return
- -2.13%
- +11.61%
- 1Y return
- +29.24%
- +10.36%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2005
- 2025
- News (4w)
- 6
- 6
- Recent ratings
- 25
- 9
DexCom Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
Latest DXCM
- Landmark Dexcom CONNECT Study Published in The New England Journal of Medicine, Redefining the Standard of Care for People with Type 2 Diabetes Not on Insulin
- Barclays initiated coverage on Dexcom with a new price target
- Dexcom Schedules Third Quarter 2026 Earnings Release and Conference Call for October 29, 2026 at 4:30 p.m. Eastern Time
- Dexcom U Enters Season 5 With a Record Roster and Evidence That Diabetes Stigma Among Young Athletes Is Fading
- EVP Chief People & Culture Off Stern Sadie sold $220,975 worth of shares (2,565 units at $86.15) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 123,478 units (SEC Form 4)
- Dexcom Publishes New Report During EASD 2026 on Type 2 Diabetes Revealing Critical Opportunity for Global Diabetes Care
- EVP Chief Legal Compliance Off Brown Michael Jon sold $142,868 worth of shares (1,700 units at $84.04) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 99,885 units (SEC Form 4)
- Director Augustinos Nicholas sold $679,769 worth of shares (8,089 units at $84.04) as part of a pre-agreed trading plan (SEC Form 4)
- DexCom Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- Dexcom Promotes Jereme Sylvain to Chief Operating Officer
Latest KMTS
- Director Cohen Raymond W sold $97,504 worth of shares (3,330 units at $29.28), decreasing direct ownership by 6% to 54,790 units (SEC Form 4) (tax liability)
- Kestra Medical Technologies Earns Five-Star Rating on Newsweek’s List of America’s Greatest Mid-Market Companies
- SEC Form 144 filed by Kestra Medical Technologies Ltd.
- CAIRDAC Announces the Appointment of Raymond W. Cohen as Chairman of its Board of Directors
- Director Kwo Elizabeth sold $97,268 worth of shares (4,010 units at $24.26), decreasing direct ownership by 22% to 14,116 units (SEC Form 4) (withholding obligation)
- SEC Form 144 filed by Kestra Medical Technologies Ltd.
- SEC Form 10-Q filed by Kestra Medical Technologies Ltd.
- Kestra Medical Technologies Ltd. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Kestra Medical Technologies Reports First Quarter Fiscal 2027 Financial Results
- Director Schwartz Jeffrey Lawrence sold $97,942 worth of shares (3,890 units at $25.18) and was granted 7,217 shares, increasing direct ownership by 30% to 14,236 units (SEC Form 4) to satisfy tax liability